𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
𝗦𝗶𝗼𝗻𝗻𝗮 𝗹𝗶𝗰𝗲𝗻𝘀𝗲𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗰𝘆𝘀𝘁𝗶𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗮𝘀𝘀𝗲𝘁𝘀 𝗳𝗿𝗼𝗺 𝗔𝗯𝗯𝗩𝗶𝗲 𝘀𝗵𝗼𝗿𝘁𝗹𝘆 𝗮𝗳𝘁𝗲𝗿 𝗹𝗮𝗿𝗴𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 Sionna Therapeutics Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in …Michael Cloonan https://lnkd.in/deCdSr7Y
-
𝗦𝗰𝗼𝗿𝗽𝗶𝗼𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟱𝟬𝗠 𝘄𝗶𝘁𝗵 𝘀𝗶𝗴𝗵𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝘄𝗮𝘃𝗲 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 Scorpion Therapeutics has a fresh $150 million to work with as it moves an experimental breast cancer drug through clinical trials in an effort to …Adam Friedman, MD, PhD https://lnkd.in/d9nD3CB8
Scorpion raises $150M for next wave of targeted cancer therapies
https://endpts.com
-
𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝘀𝗰𝗲𝗻𝗲𝘂𝗿𝗼𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟬𝟬𝗠 A small Swiss Biotech Association has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 …Barbara A. Asceneuron SA https://lnkd.in/dxmSFZ5c
Alzheimer’s biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau
https://endpts.com
-
𝗟𝗲𝘅𝗲𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀' 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗵𝗼𝘄𝘀 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗙𝗿𝗶𝗲𝗱𝗿𝗲𝗶𝗰𝗵'𝘀 𝗮𝘁𝗮𝘅𝗶𝗮 𝗰𝗮𝗿𝗱𝗶𝗼𝗺𝘆𝗼𝗽𝗮𝘁𝗵𝘆 𝘄𝗶𝘁𝗵 𝗲𝗮𝗿𝗹𝘆 𝗱𝗮𝘁𝗮 Lexeo Therapeutics thinks its gene therapy has the potential for accelerated approval following positive interim data from two early-stage studies, Nolan Townsend https://lnkd.in/dPj7ZTeD
Updated: Lexeo Therapeutics’ gene therapy shows potential for Friedreich’s ataxia cardiomyopathy with early data
https://endpts.com
-
𝗔𝗿𝘁𝗶𝘃𝗮 𝗮𝗶𝗺𝘀 𝗳𝗼𝗿 $𝟭𝟭𝟲𝗠 𝗶𝗻 𝘀𝗲𝗰𝗼𝗻𝗱 𝗮𝘁𝘁𝗲𝗺𝗽𝘁 𝗮𝘁 𝗜𝗣𝗢 𝘁𝗼 𝗯𝗼𝗼𝘀𝘁 𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC…Fred Aslan https://lnkd.in/dyMVXr3h
Artiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline
https://endpts.com
-
𝗜𝗽𝘀𝗲𝗻 𝘁𝗮𝗸𝗲𝘀 𝗼𝗻 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 𝗔𝗗𝗖, 𝘁𝗵𝗶𝘀 𝘁𝗶𝗺𝗲 𝗳𝗿𝗼𝗺 𝗮 𝗖𝗵𝗶𝗻𝗮-𝗯𝗮𝘀𝗲𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 Ipsen is adding a second antibody-drug conjugate to its plate. The French drugmaker said Thursday that it has inked a global licensing agreement for a … https://lnkd.in/dSpqudNe
Ipsen takes on another ADC, this time from Foreseen Biotechnology
https://endpts.com
-
𝗝𝗣𝗠’𝘀 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗖 𝘁𝗲𝗮𝗺 𝗶𝘀 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 J.P. Morgan SAMARTH LIFE SCIENCES PRIVATE LIMITED hired a leading biotech investor as it continues to build out its team after having disclosed two recent investments … https://lnkd.in/dMTzgY7V
JPM’s life sciences VC team is growing
https://endpts.com
-
𝗜𝗹𝗹𝘂𝗺𝗶𝗻𝗮 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗼𝗿 𝗘𝗹𝗲𝗺𝗲𝗻𝘁 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟮𝟳𝟳𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗗 Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the https://lnkd.in/dt6_STJ3
Illumina competitor Element Biosciences raises $277M in Series D
https://endpts.com
-
𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴, 𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀-𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰 Sanofi plans to invest €1.5 billion in its Frankfurt plant, reversing plans to relocate production to France. Eli Lilly and Company invests $140 million upfront in Radionetics Oncology, with an option to acquire the company for $1 billion. GSK acquires CureVac's mRNA flu and COVID-19 vaccines for €400 million upfront, with potential payments up to €1.05 billion. Emergent BioSolutions secures over $250 million from the US for strategic stockpile vaccines and treatments. Beacon Therapeutics raises $170 million to advance its lead eye disease therapy in clinical trials. Exsilio Therapeutics, led by a former Moderna exec, launches with $82 million to tackle genetic medicine challenges. Moderna secures $176 million from BARDA to develop a bird flu vaccine using mRNA technology. Cartesian Therapeutics raises $130 million through PIPE financing and reports positive Phase 2b trial results for myasthenia gravis treatment. Eli Lilly and Company's Alzheimer's Association® drug Kisunla™ (donanemab-azbt) HCP gains FDAQRC approval, offering monthly treatment for cognitive decline, priced at $32,000 per year. Novo Nordisk invests $4.1 billion in a new plant in North Carolina, creating 1,000 jobs to produce obesity and chronic disease treatment. Sanofi looking to sell its consumer healthcare division, Opella-hospitality valued at $20 billion. ANI Pharmaceuticals, Inc. acquires Alimera Alimera Sciences Ophthalmologie GmbH GmbH for $381 million. AbbVie acquires Celsius Therapeutics for $250 million, gaining a Phase I candidate drug for inflammatory bowel disease. Alumis raises $210 million in a major IPO, but below expectations, supported by a $40 million private stock sale. Roche partners with Ascidian Therapeutics to target neurological diseases, potentially paying up to $1.8 billion plus royalties. EUROAPI plans €350-400 million investment, including Sanofi support, with restructuring and job cuts to focus on high-value APIs.